These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

957 related items for PubMed ID: 15880876

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Access for the terminally ill to experimental medical innovations: a three-pronged threat.
    Bender S, Flicker L, Rhodes R.
    Am J Bioeth; 2007 Oct; 7(10):3-6. PubMed ID: 17926208
    [No Abstract] [Full Text] [Related]

  • 23. Ethics. Senate inquiry on research conflicts shifts to grantees.
    Kaiser J.
    Science; 2008 Jun 27; 320(5884):1708. PubMed ID: 18583586
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Financial disclosure by clinical investigators--FDA. Final rule; action on petition for reconsideration.
    Fed Regist; 1998 Dec 31; 63(251):72171-81. PubMed ID: 10344800
    [Abstract] [Full Text] [Related]

  • 26. Trials and tribulations: new pressure on drug companies to reveal all about their clinical tests.
    Economist; 2004 Jun 19; 371(8380):62-3. PubMed ID: 15457617
    [No Abstract] [Full Text] [Related]

  • 27. Advisors may urge NIH to seek out industry support for clinical trials.
    Appel A.
    Nature; 1995 Nov 09; 378(6553):116. PubMed ID: 7477301
    [No Abstract] [Full Text] [Related]

  • 28. NIH encourages translational collaboration with industry.
    Wadman M.
    Nat Rev Drug Discov; 2010 Apr 09; 9(4):255-6. PubMed ID: 20224566
    [No Abstract] [Full Text] [Related]

  • 29. FDA publishes conflict of interest rules for clinical trials. Food and Drug Administration.
    James JS.
    AIDS Treat News; 1998 Mar 06; (No 290):8. PubMed ID: 11365123
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Scripps to get less from Sandoz.
    Anderson C.
    Science; 1994 May 20; 264(5162):1077. PubMed ID: 8178164
    [No Abstract] [Full Text] [Related]

  • 32. Major issues in marketing regulation.
    Pines WL.
    Food Drug Law J; 1997 May 20; 52(3):297-302. PubMed ID: 10343028
    [No Abstract] [Full Text] [Related]

  • 33. Biotechnology transfer at the National Institutes of Health.
    Chen PS.
    Qual Assur; 1993 Dec 20; 2(4):345-52. PubMed ID: 7952969
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Orphan products development and some methods for maximizing the usefulness of research on rare diseases.
    Finkel MJ.
    Prog Clin Biol Res; 1985 Dec 20; 197():11-8. PubMed ID: 4070285
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Orphan drugs: some legal, ethical and economics aspects].
    Pabst JY.
    Rev Epidemiol Sante Publique; 2001 Sep 20; 49(4):387-96. PubMed ID: 11567205
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Large clinical trials in epilepsy: funding by the NIH versus pharmaceutical industry.
    Privitera M.
    Epilepsy Res; 2006 Jan 20; 68(1):52-6. PubMed ID: 16377139
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 48.